Read on Twitter
It's #WorldCancerDay and we @NatureMedicine are fortunate to work with the amazing #cancerresearch community to share exciting and impactful #translational and #clinical studies on the prevention, diagnosis and treatment of #cancer. Here’s a selection of papers published in 2020!
A prospective, multicenter, case–control clinical trial evaluates the potential of #artificialintelligence for providing accurate bedside #diagnosis of patients with #braintumors https://www.nature.com/articles/s41591-019-0715-9 #AI #NMEDClinical @DanOrringerMD
Results from an expansion cohort of the PROFILE 1001 trial describe the anti-tumor activity of crizotinib in patients with non-small cell #lungcancer harboring a MET exon 14 alterations https://www.nature.com/articles/s41591-019-0716-8 #NMEDClinical #PrecisionOncology @alexdrilon
Genetically engineered 
mouse models representing the spectrum of human cutaneous #melanoma provide a platform for studying clinical responses to #immunotherapy https://www.nature.com/articles/s41591-020-0818-3 @NCIResearchCtr
mouse models representing the spectrum of human cutaneous #melanoma provide a platform for studying clinical responses to #immunotherapy https://www.nature.com/articles/s41591-020-0818-3 @NCIResearchCtr
The phase 2a COMBAT trial combining CXCR4/PD-1 co-inhibition in metastatic #pancreaticcancer patients shows encouraging clinical responses in association with enhanced anti-tumor immune activation https://www.nature.com/articles/s41591-020-0880-x @DrMhidalgo #NMEDClinical #immunotherapy #WorldCancerDay
A pooled analysis of tumors from patients with advanced #kidneycancer suggests that response to PD-1 blockade depends on both #Tcell infiltration and enrichment of tumor-intrinsic somatic alterations https://www.nature.com/articles/s41591-020-0839-y @DrChoueiri @BraunMDPhD @DanaFarber #WorldCancerDay
A new approach for whole-genome sequencing of plasma circulating tumor DNA allows for dynamic monitoring of disease burden and ultra-sensitive detection of minimal residual disease https://www.nature.com/articles/s41591-020-0915-3 #liquidbiopsies @landau_lab #WorldCancerDay
A phase 2 clinical trial of anti-PD-1 #immunotherapy in patients with #leptomeningealdisease showed treatment was safe and associated with a 3 month overall survival of 60% https://www.nature.com/articles/s41591-020-0918-0 #metastasis #breastcancer #NMEDClinical @MGHMedicine #WorldCancerDay
Bispecific #CARTcells targeting CD20 and CD19 demonstrate an excellent safety profile and high clinical efficacy in patients with non-Hodgkin #lymphoma and chronic lymphocytic #leukemia 
https://www.nature.com/articles/s41591-020-1081-3 #NMEDClinical @MedicalCollege #WorldCancerDay
https://www.nature.com/articles/s41591-020-1081-3 #NMEDClinical @MedicalCollege #WorldCancerDay
Along with @NatureGenet, we co-produced a collection of #cancerresearch Milestones in the past 20 years, with pieces written by editors from the @NatResCancer group https://go.nature.com/3n0h3RQ #WorldCancerDay
We look forward to publishing more papers that aid cancer patients and their families. Please feel free to get in touch with our #cancer editor @FJCarmonas or our #immunotherapy editor @SaheliSadanand if there are projects you’d like to discuss! #WorldCancerDay #IAmAndIWill